Skip to main content
Download PDF

Counteracting neuroinflammation in experimental Parkinson’s disease favors recovery of function: effects of Er-NPCs administration

Journal of Neuroinflammation volume 15, Article number: 333 (2018) Cite this article

Abstract

Background

Parkinson’s disease (PD) is the second most common neurodegenerative disease, presenting with midbrain dopaminergic neurons degeneration. A number of studies suggest that microglial activation may have a role in PD. It has emerged that inflammation-derived oxidative stress and cytokine-dependent toxicity may contribute to nigrostriatal pathway degeneration and exacerbate the progression of the disease in patients with idiopathic PD. Cell therapies have long been considered a feasible regenerative approach to compensate for the loss of specific cell populations such as the one that occurs in PD. We recently demonstrated that erythropoietin-releasing neural precursors cells (Er-NPCs) administered to MPTP-intoxicated animals survive after transplantation in the recipient’s damaged brain, differentiate, and rescue degenerating striatal dopaminergic neurons. Here, we aimed to investigate the potential anti-inflammatory actions of Er-NPCs infused in an MPTP experimental model of PD.

Methods

The degeneration of dopaminergic neurons was caused by MPTP administration in C57BL/6 male mice. 2.5 × 105 GFP-labeled Er-NPCs were administered by stereotaxic injection unilaterally in the left striatum. Functional recovery was assessed by two independent behavioral tests. Neuroinflammation was investigated measuring the mRNAs levels of pro-inflammatory and anti-inflammatory cytokines, and immunohistochemistry studies were performed to evaluate markers of inflammation and the potential rescue of tyrosine hydroxylase (TH) projections in the striatum of recipient mice.

Results

Er-NPC administration promoted a rapid anti-inflammatory effect that was already evident 24 h after transplant with a decrease of pro-inflammatory and increase of anti-inflammatory cytokines mRNA expression levels. This effect was maintained until the end of the observational period, 2 weeks post-transplant. Here, we show that Er-NPCs transplant reduces macrophage infiltration, directly counteracting the M1-like pro-inflammatory response of murine-activated microglia, which corresponds to the decrease of CD68 and CD86 markers, and induces M2-like pro-regeneration traits, as indicated by the increase of CD206 and IL-10 expression. Moreover, we also show that this activity is mediated by Er-NPCs-derived erythropoietin (EPO) since the co-injection of cells with anti-EPO antibodies neutralizes the anti-inflammatory effect of the Er-NPCs treatment.

Conclusion

This study shows the anti-inflammatory actions exerted by Er-NPCs, and we suggest that these cells may represent good candidates for cellular therapy to counteract neuroinflammation in neurodegenerative disorders.

Background

Parkinson’s disease (PD) is characterized by dopaminergic (DA) denervation of the striatum and progressive death of DA neurons in the substantia nigra pars compacta (SNpc) [1]. Neuroinflammation has a role in several neurodegenerative diseases; though it may not be considered the primary cause, it contributes to the symptomatic phase [2]. Several lines of research suggest that neuroinflammation is the major central event in dopaminergic neural cell death in PD [3,4,5]. In postmortem SN from human PD brains, microglia results activated, lymphocytes are infiltrated [2, 6], and in cerebrospinal fluids, there are high levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF), cyclooxygenase-2 (COX-2), interleukin-1beta (IL-1beta), and IL-18 [7, 8]. It has been suggested that in CNS neurodegeneration, neuronal damage may lead to the activation of microglia and astrocytes that in turn amplify the inflammatory response through chemokine secretion. This enhances CNS infiltration by peripheral immune cells. Studies in the acute neurotoxic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model provided evidences that neuroinflammatory processes can contribute to nigral DA neuronal death [9,10,11]. Both the genetic deletions of microglial effectors [12] and the suppression of T lymphocytes [6] reduced neuronal loss suggesting that neuroinflammation in PD may actively participate in neuronal death. The “principal mechanism” that links the inflammatory response with neurodegeneration remains to be fully clarified. However, it is recognized that neuronal degeneration itself and in particular the accumulation and release of alpha-synuclein aggregates by the injured DA neurons early in the disease process [13], may act as a signal, and can activate glial cells to produce and release a variety of pro-inflammatory molecules, exacerbating microglia activation and neuronal cell death [14,15,16,17,18]. Within this scenario, the major players are the microglia, the reactive astrocytes, and the infiltrating monocyte-derived macrophages [19]. Upon injury, activated M1-like microglia proliferates and participates in clearing cell debris in the early stages but may exacerbate brain injury through the production of neurotoxic substances, especially when it is overactivated for prolonged periods [20]. In the M2-like phenotype, microglia has anti-inflammatory and neuron-reparative roles, protecting the damaged tissue by removing cell debris and releasing anti-inflammatory cytokines needed for tissue repair [21]. Current treatments for PD are only symptomatic and have no effects on the ongoing neurodegeneration [22]. The ideal therapeutic treatment for PD should have both symptomatic and restorative effects aimed at preserving midbrain DA neurons from degeneration [23, 24]. In this sense, adult neural stem cells grafting into animal experimental models of neurodegenerative diseases have shown beneficial effects promoting both trophic and anti-inflammatory actions [25,26,27,28,29,30,31]. Recently, we reported the therapeutic potential of erythropoietin-releasing neural precursors cells (Er-NPCs) intrastriatally infused in a preclinical model of PD, obtained upon the administration of MPTP [30, 32]. After the unilateral transplantation into the striatum of MPTP-treated C57BL/6 mice, Er-NPCs were vital and capable of engrafting into the recipient’s brain. Er-NPC-treated animals improved their typical motor deficits within 3 days of cell transplantation, and this was accompanied by significant sparing of SN neurons. All these features and effects are likely dependent on erythropoietin’s (EPO) release since all of these were abolished by the co-injection of Er-NPCs with anti-EPO (aEPO) or anti-EPO-receptor (aEPO-R) antibodies. Little is known about the anti-inflammatory actions of Er-NPCs transplant in PD brains. Here, we focus on the study of this aspect and report that a rapid anti-inflammatory effect was evident 24 h after Er-NPCs transplant with the decrease of early pro-inflammatory cytokines mRNA levels (e.g., IL-1alpha, TNF). This effect was maintained for the following days, and IL-6 mRNA levels were significantly reduced as far as 7 days after transplantation. At the end of the 2-week observational period, histological data confirmed the reduction of activated microglia marker expression (GFAP and Iba1) and macrophages infiltration (CD68). Moreover, at the same time point, we observed the increase of markers associated with the M2-like protective phenotype. Co-injection of Er-NPCs with aEPO antibody neutralizes the Er-NPCs anti-inflammatory activity, strongly indicating that this effect is mediated by EPO released from Er-NPCs.

Methods

Animals and study approval

Procedures involving animals and their care were conducted in conformity with the Italian Guidelines for Laboratory Animals, which conform to the European Communities Directive of September 2010 (2010/63/UE), and the Review Committee of the University of Milan gave its approval to the study (No 2/2013). Male C57BL/6 mice (Charles River, Milan, Italy), 12–16 weeks old and weighing 20–24 g, were kept for at least 7 days before the experiments and housed in standard conditions (22 ± 2 °C, 65% humidity, and a 12-h light-dark cycle) with food and water ad libitum. Moreover, in order to make them amenable, the animals were accustomed to the behavioral tests (horizontal and vertical, see below for details) daily for 1 week prior to MPTP injection.

Er-NPCs isolation

Erythropoietin-releasing neural precursors cells (Er-NPCs) expressing green fluorescent protein (GFP) were isolated 6 h postmortem from adult C57BL/6-Tg(UBC-GFP)30Scha/J mice weighing 25–30 g (Charles River) as previously described [29, 33, 34].

Animal treatments

Experimental animals were divided into five groups: (1) control (CTRL, healthy animals, n = 24), (2) MPTP-treated mice (MPTP, n = 24), (3) MPTP-treated mice infused with PBS (SHAM, sham-operated; n = 18), (4) MPTP-treated mice transplanted with Er-NPCs (MPTP + Er-NPCs, n = 24), (5) MPTP-treated mice transplanted with Er-NPCs and anti-erythropoietin antibody (MPTP + Er-NPCs + aEPO, n = 12). Anti-erythropoietin antibody (sc-7956, Santa Cruz Biotechnology) was infused at the final concentration of 3 μg/ml [29, 30, 33, 35]. Parkinsonism was induced by intraperitoneal (i.p.) administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice following the acute paradigm with a small modification. Briefly, animals were administered a double dose of MPTP hydrochloride: a first i.p. injection of MPTP (36 mg/kg) and a second i.p. injection of MPTP (20 mg/kg) after 7 days. Er-NPCs-treated animals were transplanted with 5 × 104 cells/μl (5 μl) GFP expressing Er-NPCs, according to the following stereotaxic coordinates in relation to bregma: 0.1 mm posterior, 2.4 mm mediolateral, and 3.6 mm dorsal at the level of left striatum [36]. Please see Table 1 for a detailed number of animals for each group at specific time points. For gene expression analyses, animals from each group were sacrificed by cervical dislocation; their brains were removed and dissected. Immediately after dissection, the whole striatum, frontal cortex, and midbrain were frozen in dry ice until they were assayed. For immunohistochemistry analyses, animals from each group were anesthetized by i.p. injection of sodium pentobarbital (65 mg/kg), perfused through the left ventricle with 50 mL of saline solution, and fixed with 200 mL of 4% paraformaldehyde in 0.1 mol/L PBS. The brains were subsequently removed from the skulls and then cryoprotected at 4 °C in sucrose 300 g/L and 0.1 mol/L PBS solution for further sectioning.

Table 1 Number of animals used for experiments. All animals were tested for behavioral performances
Full size table

Behavioral tests

To investigate the recovery of motor dysfunction after cell transplantation, two different behavioral tests were performed: horizontal and vertical grid tests [30, 32, 37, 38]. Each animal was tested twice at each time point.

Horizontal grid test

The grid apparatus was constructed according to Tillerson and co-workers [30, 32, 37]. The animal was videotaped for 30 s, and the videos were replayed for percentage forepaw fault analysis using a recorder with slow motion option. The number of unsuccessful forepaw steps divided by the total number of attempted forepaw steps was evaluated [37]. The mice were acclimatized to the grid twice a day for 1 week, before MPTP treatment. Three observers (ZG, FR, MM) in blind rated each trial for forepaw faults per step.

Vertical grid test

The vertical grid apparatus was constructed according to Kim and co-workers [30, 32, 38]. For this test, the mouse was placed 3 cm from the top of the apparatus, facing upwards, and was videotaped when turning around and climbing down. The score reported was the time required by the mouse to make a turn, climb down, and reach the bottom of the grid with its forepaw within 180 s [30, 32, 38]. Before MPTP administration, mice were acclimatized to the grid twice a day for 1 week. The analysis was performed by three observers in blind (ZG, FR, MM).

Olfactory test

For this test, mice were food deprived for 20 h before the test. A corn chip was buried under their bedding (1 cm) in a corner of the cage. Each mouse was positioned at the center of the testing cage, and the time to retrieve and bite the corn chip was measured [30]. The analysis was performed by three observers in blind (ZG, FR, MM).

Immunohistochemistry and quantitative analysis

Immunohistochemistry analyses were performed on 20 μm coronal section of the whole brain cut at − 25 °C using a cryostat (Leica), and slides were collected onto glass slides and rinsed with PBS and treated with blocking solution (10% NGS, 0.2% Triton X-100) following our previously published protocols [30, 32]. The following primary antibodies were used: monocyte/macrophages (MOMA/CD68, 1:25; Millipore), CD86 (1:200; Abcam), mannose receptor (CD206, 1:200; GeneTex), GFAP (1:1000; Covance), Iba1 (1:250; Abcam), CD11b (1:200; Abcam), tyrosine hydroxylase (TH, 1:500; Millipore), and DAT (1:200; Millipore). The following secondary antibodies were used: 546 goat anti-rabbit IgG (1:200; Alexa), 546 goat anti-mouse IgG (1:200; Alexa), 546 goat anti-rat IgG (1:200, Alexa), and 488 donkey anti-rabbit IgG (1:200, Alexa). Images were acquired using standardized confocal microscopy (Leica SP2 confocal microscope with He/Kr and Ar lasers; Heidelberg, Germany). Images of striatum immunostaining were acquired in the region corresponding to bregma 2.80/3.52 mm as indicated in the Paxinos and Franklin atlas [39]. Microphotographic digital analysis was performed using the ImageJ software [30, 32, 40]. The quantification of the positive pixels versus the negative background elicits an index score that includes the contributions from fibers and neuronal somata. The immunostaining conditions were the same for all sections analyzed; staining solutions and reaction times were the same. The microscope light intensity of the laser was the same for the analysis of all given brain sections and for determining the background optical density. Co-localization in Fig. 1 was analyzed over a 3D field obtained by stacking confocal planes acquired using standardized confocal microscopy (Leica SP (confocal microscope); Heidelberg, Germany).

Fig. 1
figure 1

Er-NPCs engraft in the recipient’s brain and differentiate in TH-positive neurons. Confocal images of Er-NPCs intrastriatal distribution (green) 14 days after transplantation in the coronal sections taken from Er-NPCs-injected MPTP mouse brains (bars 50 μm). Co-expression of the cytoplasmic protein TH (red) and GFP (green) within a cell suggests dopaminergic differentiation of the transplanted Er-NPCs during migration. The histogram reports the quantification of positive cells to the TH marker in 18 different fields for each condition (n = 6 mice each group; 3 fields for mouse) (see the “Methods” section). Quantification was done by ImageJ picture analysis. *p < 0.05. Data reported in the histogram are expressed as average ± SD and refer to three brains for each experimental condition

Full size image

THP1 co-cultures with Er-NPCs

THP1 cells were seeded with fresh RPMI medium supplemented with 3% FBS on six trans-well plates at the concentration of 5 × 105 cells/well for co-culture experiment and activated with 50 ng/ml PMA. Twenty-four hours after seeding, the THP1 was stimulated adding 1 μg/ml LPS for 1 h. For co-culture experiments, Er-NPCs were dissociated, counted, and re-suspended in the THP1 medium at the concentration of 4 × 105 cells/well. Co-culture of THP1 and Er-NPCs with or without aEPO antibody (5 μg/ml) was performed using 0.4 μm pore size trans-well inserts (Corning). After 3 h of co-culturing, inserts were removed and the THP1 were isolated for RNA extraction and real-time RT-PCR. Dexamethasone was used (100 μM) as anti-inflammatory positive control [41].

RNA extraction and real-time PCR

Gene expression analyses were performed 7 days after transplant (n = 6 mice for each group) in striatum homogenates [29, 33]. The left and right striatum regions were dissected out rapidly, frozen on dry ice, and stored at − 80 °C for further analyses. Total RNA was extracted using TRIZOL® reagent (Life Technologies) following the manufacturer’s instructions, quantified, and processed as described [42, 43]. Total RNA (1 μg) was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer’s instructions. Real-time RT-PCR was performed with StepOnePlus™ Real-Time RT-PCR System (Thermo Fisher) using iQ SYBR Green Supermix (Bio-Rad). Primers were designed using Oligo Perfect Designer Software (Life Technologies) and were checked using the BLASTn tool on NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch), assessing in silico the specific targeting of the gene. Furthermore, in each RT-PCR reaction, the Tm peak was analyzed, and only single peak results (indicating specific amplification of one product) were deemed valid. A negative control analysis with no cDNA template was also performed in each RT-PCR to ensure that no contamination was present when performing the reaction. Primer sequences are reported in Table 2. Amplification conditions were AmpliTaq activation 95 °C for 10 min, PCR denaturation step 95 °C for 15 s, PCR annealing and elongation step 60 °C for 1 min, and 40 cycles of PCR were performed. Genes were quantified in triplicates, and 18S was used as housekeeping gene. Gene expression was calculated using the 2−ΔΔCt method.

Table 2 Primer sequences used to study gene expression
Full size table

Statistical analyses

Statistical analyses between groups were evaluated using GraphPadPrism 4.00 version, and data are expressed as mean ± SD. Behavioral data were analyzed with a two-way ANOVA model with time and group (CTRL, MPTP, SHAM, MPTP + Er-NPCs, and MPTP + Er-NPCs + aEPO) as factors. The null hypothesis was rejected when p < 0.05. Gene expression data were analyzed in triplicate and results were expressed as the average of six animals. The expression pattern of each gene was analyzed by one-way ANOVA followed by Bonferroni’s multiple comparisons test to assess statistical significance.

Results

Transplanted Er-NPCs integrate into the damaged host brain and promote a rapid recovery of function

The murine model of Parkinson’s disease was obtained by the administration of MPTP neurotoxin to C57BL/6 mice, following the paradigm reported previously [30, 32] (see the “Methods” section and Additional file 1 for details). Two weeks post-injection, transplanted Er-NPCs were engrafted in the recipient’s brain. Figure 1 shows that transplanted Er-NPCs migrate from the injection site to different brain sites. Their morphology looks more differentiated presenting a developed soma of good size with abundant neurite projections in the recipient striatum. Quantitative co-localization analyses performed in the striatum sections 2 weeks post-injection indicate that 70.01% (± 5.6) of engrafted Er-NPCs had migrated more than 3.25 mm following a dorso-ventral pathway, supporting previously reported results [30]. Migration is at least of 2.3 mm from the injection site following a rostro-caudal pathway (not shown) [30] and a minor percentage of cells (28.58% ± 1.42) even reached the substantia nigra ipsilateral and contralateral to the injection site [30]. A large portion of the grafted cells are localized within the striatum, more than 4–5 mm from the injection site, and express markers of mature neurons, such as Map2 and NeuN, while only a lower percentage of them was positive to NG2 and Nestin (82.30 ± 6.88% NeuN; 71.52 ± 9.45% MAP-2, 38.53 ± 5.81% NG2; 29.71 ± 12.20% Nestin) [30, 32]. TH expression is present in cells engrafted in the striatum and migrated far from the injection site (80% of GFP+-Er-NPCs localized more than 5 mm from the injection site) (Fig. 1). The evaluation of animals’ recovery of function was monitored with horizontal and vertical grid tests for 2 weeks after Er-NPCs infusion (2.5 × 105 cells/brain) (Fig. 2) [30, 32]. The administration of the neurotoxin MPTP causes damages to the nigrostriatal projections. This leads to the increase of forepaw faults of the anterior paw, as it can be appreciated in the horizontal grid test (Fig. 2a), and of the time taken to descend from the grid in the specific test (Fig. 2b). The functional recovery due to intra-striatal injection of Er-NPCs is already detectable in the third day after the transplant as the percentage of forepaw faults in mice treated with the Er-NPCs is 44.55% ± 2.5% compared to 83.02 ± 2.76% of the MPTP animals group. The initial functional recovery observed in animals treated with Er-NPCs is maintained for the entire observational period. In the vertical grid test, the differences in score between motor features of treated mice (MPTP + Er-NPCs) and not treated mice (MPTP) are highly more appreciable (Fig. 2b). The action of Er-NPC transplantation on the promotion of functional performances is also appreciable on the recovery of olfactory capabilities caused by MPTP evaluated by means of olfactory test (Additional file 2) [30].

Fig. 2
figure 2

Er-NPCs promote functional recovery. Horizontal (a) and vertical (b) grid tests were used for the behavioral analysis, and the percentage of forepaw faults and the time for descending the grid are shown in the graphs. Five groups of animals were analyzed: (1) control (CTRL, healthy animals, n = 24), (2) MPTP-treated mice (MPTP, n = 24), (3) MPTP-treated mice infused with PBS (SHAM, sham-operated; n = 18), 4) MPTP-treated mice transplanted with Er-NPCs (MPTP + Er-NPCs, n = 24), and (5) MPTP-treated mice transplanted with Er-NPCs and anti-erythropoietin antibody (MPTP + Er-NPCs + aEPO, n = 12). Data are expressed as mean ± SD. Statistical analysis was performed with two-way ANOVA test followed by Bonferroni post-test. °°°p < 0.001; °°p < 0.01 vs CTRL; ***p < 0.001vs MPTP

Full size image

Er-NPCs grafts promote the rescue of endogenous TH-positive projections in the recipient striatum

The protective action of engrafted Er-NPCs was assessed by investigating the dopaminergic markers in the engrafted striatum. By performing quantitative confocal laser microscopy on striatal sections, we found that Er-NPCs significantly counteracted the MPTP-induced loss of both striatal DAT and TH-positive innervations (Fig. 3). The TH expression was also evaluated in the substantia nigra, and a concordant pattern was observed (Fig. 3) [30, 32].

Fig. 3
figure 3

Er-NPCs promote the recovery of DAT and TH immunoreactivity. Confocal images of dopamine transporter (DAT) staining (green) (a) and tyrosine hydroxylase (TH) (showed in red) (b); of healthy mice (CTRL), mice treated with MPTP (MPTP), and MPTP infused with Er-NPCs (MPTP + Er-NPCs). Scale bars represent 50 μm. The quantification of fluorescence, represented in the diagram, was performed with the software ImageJ (NIH). The data reported in the diagram are referred to the mean ± SD (n = 6 mice each group; three fields for mouse). ***p < 0.001; *p < 0.05 vs CTRL; °°p < 0.01; °p < 0.05 vs MPTP; ###p < 0.001; #p < 0.05 vs MPTP + Er-NPCs

Full size image

Er-NPCs transplantation counteracts pro-inflammatory cytokines expression in MPTP-recipient mice

MPTP’s administration in models of PD is known to result in an inflammatory response mediated by an increased expression of neuro-inflammatory cytokines [2, 9, 44, 45]. We aimed to investigate the expression of neuroinflammatory cytokines, quantifying with real-time RT-PCR the mRNA levels of selected molecules. The MPTP administration causes a strong increase in the mRNA levels of the pro-inflammatory cytokines IL-1alpha and TNF (Fig. 4). The administration of Er-NPCs counteracts this phenomenon reducing these cytokines’ expression as early as 24 h after cells infusion (Fig. 4). This effect is significantly evident in the area of the striatum ipsilateral to the transplant. The expression of other interleukins (IL-6, IL-8, IL-10) and neurotrophic growth factors (BDNF, NGF) was also evaluated 24 h after Er-NPCs infusion without observing any significant differences between the Er-NPCs-treated group (MPTP + Er-NPCs) and the not-treated one (MPTP) (data not shown). The effect of the transplant is further maintained, as the significant reduction of TNF is still observed 7 days after the Er-NPCs infusion (Fig. 5a). IL-6, a pro-inflammatory cytokine, and IL-10, an anti-inflammatory interleukin, are highly expressed in the late response stage [45]. Seven days after the injection of Er-NPCs, IL-6 increased by sixfold in MPTP-treated mice compared to the correspondent cerebral area of control healthy animals (Fig. 5b). The levels of IL-6 were reduced in the left striatum (ipsilateral to the transplant) of Er-NPCs-infused MPTP mice, while the action of the transplanted cells was not evident in the right striatum of recipient mice (contralateral to the transplant). Conversely, the levels of expression of anti-inflammatory cytokine IL-10 were significantly increased in MPTP mice treated with Er-NPCs compared to the MPTP ones both in the left and right striatum (Fig. 5b).

Fig. 4
figure 4

Evaluation of pro-inflammatory cytokines after 24 h (IL-1alpha, TNF). The levels of early cytokines were evaluated with real-time RT-PCR 24 h after Er-NPCs infusion (IL-1alpha, TNF). The quantification was conducted separately in the both hemispheres (right and left). 18S was used as housekeeping gene. This study was conducted in triplicate on six different brain samples. The data reported in the histogram are expressed as mean ± SD. °°°p < 0.001 vs CTRL; ***p < 0.001; **p < 0.01; *p < 0.05 vs MPTP; ###p < 0.001; ##p < 0.01 vs SHAM

Full size image
Fig. 5
figure 5

Evaluation of pro-inflammatory and anti-inflammatory cytokines (IL-1alpha, TNF; IL-6 and IL-10) 7 days after Er-NPCs transplant. The quantification was conducted by real-time RT-PCR separately in both hemispheres (right and left). 18S was used as a housekeeping gene. This study was conducted in triplicate on six different brain samples. The data reported in the histogram are expressed as mean ± SD. °°°p < 0.001 vs CTRL; ***p < 0.001; **p < 0.01; *p < 0.05 vs MPTP; ###p < 0.001; ##p < 0.01 vs SHAM

Full size image

Er-NPCs regulate the expression of neuroinflammatory markers in the damaged striatum of recipient animals

Different studies demonstrated that stem cells have anti-inflammatory properties [26, 46], which lead us to think that the motor recovery we observe in animals treated with Er-NPCs could be mediated by Er-NPCs’ rapid counteraction of pro-inflammatory cytokines expression. Furthermore, we wished to clarify whether this is an effect mediated by EPO released by Er-NPCs during the engraftment in the recipient striatum [30, 32]. To dissect the action of Er-NPCs on counteracting neuroinflammatory processes, we set up a series of histological analyses performed at the end of observational period (2 weeks after Er-NPCs infusion) in which a group of Er-NPC-treated animals were also co-infused with anti-erythropoietin antibody. Figure 6a shows that there are no significant changes in CD11b’s expression, a well-characterized pan-macrophage and microglia marker [47, 48], in MPTP mice or after Er-NPCs or Er-NPCs + aEPO administration. Quantitative data are reported in the histogram that shows the quantification of fluorescence intensity (Fig. 6d) and the number of cells positive to CD11b marker expression (Additional file 3). To evaluate the presence of activated astrocytes, the levels of glial fibrillary acidic protein (GFAP) were investigated (Fig. 6b) [29]. GFAP resulted increased in the striatum slides of MPTP and MPTP + ErNPCs + aEPO-treated mice, while it decreased in Er-NPCs-treated mice, both in the ipsilateral and in the contralateral striatum. The expression levels were quantified for fluorescence intensity and reported in the histogram of Fig. 6d. To investigate the presence of immune cells, we studied the microglia in the striatum after the inflammatory stimulus, evaluating the expression of Iba1 (ionized calcium-binding adapter molecule 1), a protein codified by the AIF4 gene, which indicates the presence of activated macrophages in inflamed tissues [49]. Figure 6c shows that in the striatum of MPTP animals, there is an overexpression of the Iba1 protein. In the group of MPTP mice transplanted with Er-NPCs, the presence of Iba1 resulted significantly reduced and comparable to the control healthy animals both in the left and right striatum (Fig. 6c). Furthermore, in the striatal sections obtained from MPTP animals treated with Er-NPCs + aEPO, the downregulation of Iba1 expression was prevented. Indeed, fluorescence’s quantification shows that in this case, the signal is comparable to that of sections obtained from animals belonging to the MPTP group (Fig. 6d). These data are confirmed also by the stereological counts of cells positive to the investigated markers (Additional file 3).

Fig. 6
figure 6

Er-NPCs counteract gliosis caused by MPTP. The coronal sections obtained from the brains of mice belonging to the following experimental groups (CTRL, MPTP, MPTP + Er-NPCs ipsilateral and contralateral, MPTP + Er-NPCs + aEPO ipsilateral) were labeled with the antibody CD11b (a), GFAP (b), and Iba1 (c) in red. Scale bars represent 50 μm (CD11b and GFAP) and 20 μm (Iba1). Quantification was done by ImageJ picture analysis software and reports the fluorescence intensity/pixel expressed by the studied markers in 18 different fields for each condition (n = 6 mice each group; 3 fields for mouse) (see the “Methods” section). ***p < 0.001; **p < 0.01; *p < 0.05 vs CTRL; ###p < 0.001; ##p < 0.01; #p < 0.05 vs MPTP; °°°p < 0.001 vs MPTP + Er-NPCs ipsilateral; §§§p < 0.001vs MPTP + Er-NPCs contralateral

Full size image

Studies in acute MPTP mouse models provided evidence of monocyte’s infiltration in the brain [50,51,52]. To investigate the levels of macrophages infiltration, we evaluated the expression of CD68, a marker associated with the lysosomal activity of myeloid cells [48, 53]. CD68 increases after the administration of MPTP neurotoxin (Fig. 7a), and in the ipsilateral and contralateral sections of the striatum transplanted with Er-NPCs, its immunoreactivity is significantly decreased. The histograms shown in panel d of the same figure report the quantification of fluorescence (Fig. 7d). The microglia has two different activation phenotypes, defined as M1-like (with a pro-inflammatory action) and M2-like (with an anti-inflammatory action) [54]. These two phenotypes develop different actions depending on their released mediators. The M1-like phenotype releases pro-inflammatory cytokines and other pro-inflammatory molecules such as NO and ROS. On the contrary, M2-like microglia release anti-inflammatory cytokines [20]. To discriminate between the two macrophages subtypes that infiltrate the degenerated striatum (M1 vs M2), we studied the immunoreactivity to phenotype-specific markers. In particular, we investigated the expression of CD86, marker of macrophages M1-like (Fig. 7b) and of CD206, a mannose receptor, and a typical marker of M2-like macrophages (Fig. 7c) [20]. The expression of CD86 was significantly increased in MPTP mice, while in mice treated with Er-NPCs, the levels of CD86 decreased, both in the ipsi and in the contralateral sites to the transplant (Fig. 7b). In MPTP mice co-administrated with Er-NPCs and aEPO antibody, the reduction of CD86 mediated by the cells was inhibited. An opposite pattern was observed for the CD206 marker, with a very low expression of this marker in MPTP mice and MPTP mice treated with Er-NPCs + aEPO (Fig. 7c). CD206 resulted in a high increase in MPTP mice treated with Er-NPCs (Fig. 7c). The quantification of fluorescence intensity relative to the expression of each marker is reported in Fig. 7d. Moreover, these observations are confirmed also by the stereological counts of cells positive to the investigated markers (Additional file 4).

Fig. 7
figure 7

Er-NPCs engraftment counteracts macrophages invasion and allows the switch from M1 to M2 subtype. Immunohistochemistry analysis of coronal sections obtained from the brain of healthy control animals, treated with MPTP and with MPTP + Er-NPCs ipsilateral and contralateral to the transplant site and with MPTP + Er-NPCs + aEPO ipsilateral to the transplant site. The brain sections were labeled with the antibody CD68 (a), CD86 (b), and CD206 (c) in red. Scale bars represent 50 μm (CD68, CD86, and CD 206). Quantification was done by ImageJ picture analysis software and reports the fluorescence intensity/pixel expressed by the studied markers (n = 6 mice each group; three fields for mouse) (see the “Methods” section). ***p < 0.001; **p < 0.01 vs CTRL; ###p < 0.001; ##p < 0.01; #p < 0.05 vs MPTP; °°°p < 0.001; °°p < 0.01; °p < 0.05 vs MPTP + Er-NPCs ipsilateral; §§§p < 0.001; §§p < 0.01 vs MPTP + Er-NPCs contralateral (d)

Full size image

The anti-inflammatory effect of Er-NPCs is mediated by EPO

To confirm that the anti-inflammatory actions exerted by the Er-NPCs transplanted were connected to the release of EPO, at the end of the observational period (2 weeks after transplantation) six brains for each experimental group were explanted without perfusion. The striatum and substantia nigra were dissected from each brain, total RNA was extracted, and the RNA expression of pro-inflammatory cytokines IL-6 and TNF was evaluated (Fig. 8). The results of the expression analysis show that Er-NPCs transplant significantly allows the reduction of pro-inflammatory cytokines in both the striatum and substantia nigra of recipient animals (Fig. 8). The co-administration of Er-NPCs with aEPO antibody inhibits the therapeutic effect of transplanted cells. Indeed, in these animals and in the MPTP non-transplanted animals, the levels of all the studied cytokines resulted in significant increase as opposed to control. This observation is in complete concordance with what has been observed by immunofluorescence analysis of neuro-inflammatory markers.

Fig. 8
figure 8

The co-administration of aEPO with Er-NPCs abrogated their positive effect on pro-inflammatory cytokines. At 2 weeks after transplantation, mRNA levels of IL-6 and TNF were quantified in the striatum (a) and substantia nigra (b). 18S was used as a housekeeping gene. The evaluation was performed in triplicate on six different brain samples. The data reported in the histogram are expressed as mean ± SD. ***p < 0.001 vs CTRL; ###p < 0.001 vs MPTP; $$$p < 0.001 vs SHAM; °°°p < 0.001 vs MPTP + Er-NPCs

Full size image

Er-NPCs override the pro-inflammatory cytokine production by macrophages in vitro

To further investigate whether the anti-inflammatory properties were due to the transplanted neural precursors, we performed an expression analysis of pro-inflammatory cytokines IL1-beta and TNF using an in vitro system that recapitulates the inflammatory microenvironment. THP1 cells were differentiated with PMA for 24 h (100 μM) and activated using LPS for 1 h (1 μg/ml) [55] (please see schematic representation in Fig. 9). Then, Er-NPCs were added using a trans-well approach and maintained in the co-culture trans-well system for 3 h. As expected, the THP1 macrophages showed a significant increase in the expression levels of TNF and IL1-beta mRNAs. The presence of Er-NPCs counteracted the expression of both pro-inflammatory cytokines with respect to THP1 macrophages (Fig. 9). The co-incubation with Er-NPCs in presence of anti-EPO antibody (5 μg/ml) partially inhibited the effect exerted by Er-NPCs (Fig. 9).

Fig. 9
figure 9

Er-NPCs inhibit the expression of pro-inflammatory cytokines in co-culture experiment. a Schematic of experimental set up for in vitro THP1 cells activation to macrophages and co-cultures with Er-NPCs. The assay was performed in trans-well. b mRNA expression levels of pro-inflammatory cytokines IL-1beta and TNF in co-culture experiments. mRNA levels were evaluated by real-time RT-PCR in not-treated activated THP1 versus co-culture with Er-NPCs, Er-NPCs + aEPO, and activated THP1 treated with dexamethasone (100 μM) a potent anti-inflammatory and immunosuppressive agent used as control. The co-culture assay lasted for 3 h. The experiment was repeated trice, and each point was assayed in triplicate. The data reported in the histogram are expressed as mean ± SD. ***p < 0.001 vs THP1 + LPS; ###p < 0.001 vs Er-NPCs/THP1 + LPS; °°°p < 0.001; °p < 0.05 vs Er-NPCs + aEPO/THP1 + LPS

Full size image

Discussion

Many reports have shown the ability of transplanted neural stem cells to modify the environment of the recipient tissue and give rise to positive effects in animal experimental models of PD. Here, we uncover the anti-inflammatory action exerted by engrafted Er-NPCs in an MPTP model of PD. Their transplantation promoted functional recovery and resulted in the sparing of dopaminergic nigro-striatal projections. By perceiving signals coming from the microenvironment of damaged tissue, stem cells can migrate to specific sites in the body and respond to a specific signal by releasing cytokines and modifying their own fate [56]. All of these features allow stem cells to be a possible therapeutic approach for many neurodegenerative diseases, including PD.

Here, we used accessible, stably expandable, and well-characterized erythropoietin-releasing neural precursors cells (Er-NPCs) [29,30,31,32,33,34]. The aim of this work was to investigate the mechanisms exerted by Er-NPCs transplantation in a mouse model of PD, obtained with MPTP administration, which mimics the inflammatory process related to the pathology [50,51,52, 57].

Transplanted Er-NPCs survived after transplantation, differentiated in the recipient striatum, and induced significant amelioration in functional motor symptoms caused by MPTP intoxication 3 days post-transplantation, as well as reduced pro-inflammatory cytokines 24 h after the infusion. These results support the hypothesis that the transplanted Er-NPCs inhibit the neuroinflammatory phenomena associated with Parkinsonism induced by the administration of MPTP neurotoxin, via an EPO-dependent mechanism. Moreover, although the expression of specific markers of macrophages polarization is not completely categorized [58], the transplanted neural precursors interact with the recipient microenvironment and stimulate tissue response to inflammation, supporting the transition of macrophages from M1-like phenotype to M2-like, towards a more protective action [59]. It would require specific assays such as RNASq experiments to dissect deeply the macrophages pathways involved. We have observed that there is no direct contact between M2-like macrophages (positive to CD206) and transplanted Er-NPCs, suggesting that the observed transition does not require the direct contact with the cells but can probably be ascribed to a paracrine phenomenon. The mechanism could be related to a local counteraction of inflammation and neuroprotective action mediated by EPO [30, 32, 59,60,61] on neurons and neural processes affected by MPTP. Neuroinflammation is a physiologic response to the administration of the MPTP toxin resulting in microglia activation which secretes multi-functional immunoregulatory factors, most notably TNF, IL-1 and IL-6 families, interferon gamma (IFN-gamma), and transforming growth factor beta (TGF-beta), [62, 63]. All of these factors act in context-dependent ways to modulate inflammatory processes and the permeability of the BBB [15, 64, 65]. Anti-inflammatory properties of Er-NPCs are shown by the fact that their transplant downregulates IL-6 and TNF mRNA levels and reduces macrophages invasion in the striatum and in the SNpc of recipient mice.

This is consistent with our previous work performed in experimental traumatic spinal cord injury, which reported the reduction of inflammatory cytokine levels and macrophage infiltration after the treatment with rhEPO [60] or administration of Er-NPCs [29, 33]. This seems to happen also in the present work, as there is a counter-action of the inflammatory events caused by MPTP, particularly ipsilateral to the injection site. Moreover, we observed here that transplanted Er-NPCs were able to counteract the expression of activated microglia’s markers both in the ipsi- and contra-lateral striatum. This further validates our previous evidences [30, 32] showing that the inhibition of EPO’s release by Er-NPCs influenced the striatum microenvironment by reducing endogenous EPO expression [32]. Thus, we could speculate that the action on contralateral neuroinflammation can be ascribed both to the diffusion of EPO released by engrafted precursors and by the modification of the local microenvironment [32]. The counteractive effects on astrocytes (GFAP staining reduction) are quite relevant since this type of cells are highly activated in PD and produce an elevated level of inflammatory cytokines and reactive oxygen species [66]. Moreover, such an activation is correlated with increased neuronal death [67, 68].

We found that the levels of pro-inflammatory cytokines, such as IL-1alpha, TNF, and IL-6 mRNA levels, are significantly reduced 24 h (IL1-alpha, TNF) and 1 week (IL-6) after Er-NPCs administration in contrast with IL-10, an anti-inflammatory cytokine, which resulted increased in the ipsilateral striatum 1 week after administration of Er-NPCs. The variation in the mRNA levels of cytokines is concordant with the decrease of CD86 (marker of macrophage phenotypes M1-like) and the increase of the level of CD 206 (marker of macrophages M2-like). Moreover, our results suggest that EPO released by Er-NPCs is implicated in the shift from a pro-inflammatory to a positive phagocytic state [58, 59, 69]. Phenotypic M changes are associated with no major changes in overall CD11b immunoreactivity in MPTP-treated animals transplanted with Er-NPCs with respect to CTRL. This could be explained by the fact that both resident microglia and infiltrated macrophages are positive to CD11b staining following central nervous system injuries [47, 48]. It has been shown that both phenotypes have phagocytic functions: under pro-inflammatory conditions M1-like macrophages, being toxic cells, target viable neurons, cause their death, and help in the propagation of the damage. On the other hand, under anti-inflammatory stimuli, M2-like subtype macrophages, being protective, with their phagocytic activity remove toxic cellular debris and dying cells to allow the creation a favorable microenvironment for the recovery [70, 71]. The ability of Er-NPCs to influence and limit the “pro-inflammatory activity” might be a key pathway to confer protection from PD.

This work confirmed that after the infusion, most of Er-NPCs survive (≥ 75%) [32] in the striatum and differentiate mainly in neurons [32]. The engrafted precursors migrate in the distal zones from the injection site and show a higher capacity to differentiate: 60% of these cells are positive to MAP2, and more than 80% express the NeuN marker.

This data, if considered together with the results obtained from the transplant of Er-NPCs in traumatic spinal cord injury model [29, 30], shows that these neural precursors are able to interact with the microenvironment where they are infused and differentiate to specific lineages [29, 32].

One of the most encouraging results of the pre-clinic approach that characterizes this work is the study of functional recovery in animals treated with Er-NPCs. Indeed, the motor recovery is already evident at the third day after transplant; it is further improved during the full observational period of 2 weeks, and it is maintained up to 2 months after the transplant [30]. The positive results obtained from the analysis of the motor capabilities are supported by observations obtained via immunohistochemistry analysis that demonstrate that precursor’s transplantation promotes the recovery of TH projections and DAT expression in the recipient striatum associated with the recovery of TH-positive cellular bodies in the SNpc [30]. Aiming to characterize the mechanism of action of injected Er-NPCs, we have studied the role of EPO when released by Er-NPCs [34] in vivo and in vitro. The inhibition of EPO’s action, caused by the co-administration of the aEPO antibody both in the in vivo and in the in vitro macrophage activation assay, allowed us to validate that the release of this cytokine by the Er-NPCs is one of the mechanisms responsible for their capability to counteract neuroinflammation. EPO’s neuroprotective and anti-inflammatory effects are very well studied and widely supported in the literature [72]. EPO analogs or non-erythropoietic-mutant EPO variants showed neuroprotective actions in MPTP-induced neurotoxicity and had neuro-rescue effects in rodent models of PD [73,74,75,76]. Interestingly, the administration of aEPO antibody in the in vitro macrophages activation assay only partially suppresses the effect of Er-NPCs on TNF mRNA expression levels. This suggests that the feature of Er-NPCs to act as biological disease-modifying agents should not only be due to EPO but possibly to other unknown anti-inflammatory molecules released by these cells.

Conclusion

In conclusion, the data presented in this work suggests that the adult neural precursors releasing EPO represent an interesting model of stem cell therapy approach. Er-NPCs are able to interact with and improve the microenvironment of the damaged tissue thanks to the release of protective factors such as EPO. Moreover, our data suggests that erythropoietin can be a potential pharmacological therapy useful for the treatment of Parkinson’s disease, thanks to its anti-inflammatory properties.

Abbreviations

aEPO:

Anti-EPO

aEPO-R:

Anti-EPO-R

ANOVA:

Analysis of variance

BBB:

Blood-brain barrier

BDNF:

Brain-derived neurotrophic factor

CNS:

Central nervous system

CTRL:

Control

DA:

Dopaminergic

DAT:

Dopamine transporters

DEXA:

Dexamethasone

EPO:

Erythropoietin

EPO-R:

Erythropoietin receptor

Er-NPCs:

Erythropoietin releasing neural precursors cells

FBS:

Fetal bovine serum

GFP:

Green fluorescent protein

IFN:

Interferon

IL:

Interleukin

LPS:

Lipopolysaccharide

MOMA:

Monocyte/macrophages

MPTP:

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

NGF:

Nerve growth factor

NGS:

Normal goat serum

PBS:

Phosphate-buffered saline

PD:

Parkinson’s disease

PMA:

Phorbol 12-myristate 13-acetate

RPMI:

Roswell Park Memorial Institute medium

SNpc:

Substantia nigra pars compacta

TH:

Tyrosine hydroxylase

THP1:

Human leukemia monocytic cell line

TNF:

Tumor necrosis factor

References

  1. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson’s disease. Mov Disord. 2013;28(1):24–30.

    Article  CAS  Google Scholar 

  2. Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–97.

    Article  CAS  Google Scholar 

  3. Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis: Int J Program Cell Death. 2009;14(4):478–500.

    Article  Google Scholar 

  4. Zhou Y, Lu M, Du RH, Qiao C, Jiang CY, Zhang KZ, Ding JH, Hu G. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener. 2016;11:28.

    Article  Google Scholar 

  5. Kaur B, Prakash A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson’s disease in rats. Pathophysiology. 2017;24(2):71–9.

    Article  CAS  Google Scholar 

  6. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182–92.

    CAS  PubMed  Google Scholar 

  7. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994b;180(2):147–50.

    Article  CAS  Google Scholar 

  8. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165(1–2):208–10.

    Article  CAS  Google Scholar 

  9. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;1:S210–2.

    Article  Google Scholar 

  10. Klemann CJHM, Martens GJM, Poelmans G, Visser JE. Validity of the MPTP-treated mouse as a model for Parkinson’s disease. Mol Neurobiol. 2016;53(3):1625–36.

    Article  CAS  Google Scholar 

  11. Siracusa R, Paterniti I, Cordaro M, Crupi R, Bruschetta G, Campolo M, Cuzzocrea S, Esposito E. Neuroprotective effects of temsirolimus in animal models of Parkinson’s disease. Mol Neurobiol. 2018;55(3):2403–19.

    Article  CAS  Google Scholar 

  12. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2003;100(10):6145–50.

    Article  CAS  Google Scholar 

  13. Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. Neuron. 2013;79(6):1044–66.

    Article  CAS  Google Scholar 

  14. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005;19(6):533–42.

    Article  CAS  Google Scholar 

  15. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol. 2007;150:963–76.

    Article  CAS  Google Scholar 

  16. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect. 2011;119(6):807–14.

    Article  CAS  Google Scholar 

  17. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8(1):e55375.

    Article  CAS  Google Scholar 

  18. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson’s disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 2013;5(2):113–39.

    Article  CAS  Google Scholar 

  19. Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Höglinger GU. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol. 2012;238(2):183–91.

    Article  CAS  Google Scholar 

  20. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodeg. 2015;4:19.

    Article  Google Scholar 

  21. Perry VH, Teeling J. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol. 2013;35(5):601–12.

    Article  CAS  Google Scholar 

  22. Olanow CW, Schapira AHV, Agid Y. Neurodegeneration and prospects for neuroprotection and rescue in Parkinson’s disease. Ann Neurol. 2003;53:S1.

    Article  Google Scholar 

  23. Lang AE, Espay AJ. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord. 2018;33(5):660–677. https://doi.org/10.1002/mds.27360.

  24. Kakkar AK, Singh H, Medhi B. Old wines in new bottles: repurposing opportunities for Parkinson’s disease. Eur J Pharmacol. 2018;830:115–27.

    Article  CAS  Google Scholar 

  25. Yasuhara T, Matsukawa N, Hara K, Yu G, Xu L, Maki M, Kim SU, Borlongan CV. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J Neurosci. 2006;26(48):12497–511.

    Article  CAS  Google Scholar 

  26. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci. 2006;7(5):395–406.

    Article  CAS  Google Scholar 

  27. Redmond DE Jr, Bjugstad KB, Teng YD, Ourednik V, Ourednik J, Wakeman DR, Parsons XH, Gonzalez R, Blanchard BC, Kim SU, Gu Z, Lipton SA, Markakis EA, Roth RH, Elsworth JD, Sladek JR Jr, Sidman RL, Snyder EY. Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A. 2007;104(29):12175–80.

    Article  CAS  Google Scholar 

  28. Bottai D, Madaschi L, Di Giulio AM, Gorio A. Viability-dependent promoting action of adult neural precursors in spinal cord injury. Mol Med. 2008;14:634–44.

    Article  CAS  Google Scholar 

  29. Carelli S, Giallongo T, Marfia G, Merli D, Ottobrini L, Degrassi A, Basso MD, Di Giulio AM, Gorio A. Exogenous adult post mortem neural precursors attenuate secondary degeneration, and promote myelin sparing and functional recovery following experimental spinal cord injury. Cell Transpl. 2015;24:703e719.

    Google Scholar 

  30. Carelli S, Giallongo T, Viaggi C, Latorre E, Gombalova Z, Raspa A, Mazza M, Vaglini F, Di Giulio AM, Gorio A. Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors. Neuropharmacology. 2017;119:76–90.

    Article  CAS  Google Scholar 

  31. Carelli S, Giallongo T, Gombalova Z, Merli D, Di Giulio AM, Gorio A. EPO-releasing neural precursor cells promote axonal regeneration and recovery of function in spinal cord traumatic injury. Restor Neurol Neurosci. 2017;35(6):583–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Carelli S, Giallongo T, Viaggi C, Gombalova Z, Latorre E, Mazza M, Vaglini F, Di Giulio AM, Gorio A. Grafted neural precursors integrate into mouse striatum, differentiate and promote recovery of function through release of erythropoietin in MPTP-treated mice. ASN Neuro. 2016;27:8(5).

    Google Scholar 

  33. Carelli S, Giallongo T, Latorre E, Caremoli F, Gerace C, Basso MD, Di Giulio AM, Goria A. 2014. Adult mouse post mortem neural precursors survive, differentiate, counteract cytokine production and promote functional recovery after transplantation in experimental traumatic spinal cord injury. J Stem Cell Res Transpl 2014;1:1008.

  34. Marfia G, Madaschi L, Marra F, Menarini M, Bottai D, Formenti A, Bellardita C, Di Giulio AM, Carelli S, Gorio A. Adult neural precursors isolated from post mortem brain yield mostly neurons: an erythropoietin-dependent process. Neurobiol Dis. 2011;43:86e98.

    Article  Google Scholar 

  35. Verdier F, Gomez S, Lacombe C, Mayeux P. Selected anti-Epo receptor antibodies predict Epo receptor expression. Blood. 2006;107:1892–5.

    Article  Google Scholar 

  36. Cui YF, Hargus G, Xu JC, Schmid JS, Shen YQ, Glatzel M, Schachner M, Bernreuther C. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice. Brain. 2010;133:189e204.

    Article  Google Scholar 

  37. Tillerson JL, Miller GW. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods. 2003;123:189–200.

    Article  Google Scholar 

  38. Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O. (2010). Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson’s disease. Brain Res 2010;1306:176–183.

  39. Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates, second ed. Hong Kong: Academic Press; 2001.

    Google Scholar 

  40. Jensen EC. Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec. 2013;296:378e381.

    Google Scholar 

  41. Newton R. Anti-inflammatory glucocorticoids: changing concepts. Eur J Pharmacol. 2014;5(724):231–6.

    Article  Google Scholar 

  42. JunKonishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 1993;609:29e35 Pharmacol. 2014 Feb 5;724:231–6. doi: 10.1016/j.ejphar.2013.05.035. Epub 2013.

    Google Scholar 

  43. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol. 2004;207:3233e3242.

    Article  Google Scholar 

  44. Leal MC, Casabona JC, Puntel M, Pitossi FJ. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s disease? Front Cell Neurosci. 2013;7:53.

    Article  CAS  Google Scholar 

  45. Moehle MS, West AB. M1 and M2 immune activation in Parkinson’s disease: foe and ally. Neuroscience. 2015;302:59–73.

    Article  CAS  Google Scholar 

  46. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:815e1822.

    Article  Google Scholar 

  47. Fumagalli S, Perego C, Ortolano F, De Simoni MG. CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia. 2013;61:827–42.

    Article  Google Scholar 

  48. Perego C, Fumagalli S, Zanier ER, Carlino E, Panini N, Erba E, De Simoni MG. Macrophages are essential for maintaining a M2 protective response early after ischemic brain injury. Neurobiol Dis. 2016;96:284–93.

    Article  CAS  Google Scholar 

  49. Ribak CE, Shapiro LA, Perez ZD, Spigelman I. Microglia associated granule cell death in the normal adult dentate gyrus. Brain Struct Funct. 2009;214:25–35.

    Article  Google Scholar 

  50. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999;5(12):1403–9.

    Article  CAS  Google Scholar 

  51. Wu YP, Matsuda J, Kubota A, Suzuki K, Suzuki K. Infiltration of hematogenous lineage cells into the demyelinating central nervous system of twitcher mice. J Neuropathol Exp Neurol. 2000;59(7):628–39.

    Article  CAS  Google Scholar 

  52. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9(7):917–24.

    Article  CAS  Google Scholar 

  53. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8(11):e80908.

    Article  Google Scholar 

  54. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008;29(8):357–65.

    Article  CAS  Google Scholar 

  55. McFarland AJ, Davey AK, Anoopkumar-Dukie S. Phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 monocytes as a validated microglial-like model in vitro. World Academy of Science, Engineering and Technology International Journal of Pharmacological and Pharmaceutical. Sciences. 2016;10:9.

    Google Scholar 

  56. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013;5:179ps7.

    Article  Google Scholar 

  57. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation. 2008;5:8.

    Article  Google Scholar 

  58. Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19(8):987–91.

    Article  CAS  Google Scholar 

  59. Bond WS, Rex TS. Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Front Immunol. 2014;5:523.

    Article  Google Scholar 

  60. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. ProcNatlAcadSciU S A. 2002;99(14):9450–5.

    Article  CAS  Google Scholar 

  61. Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett. 2007;425:177e182.

    Article  Google Scholar 

  62. Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’ disease. Official Publication of the FASEB J. 2003;13:1957–9.

    Article  Google Scholar 

  63. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26(Suppl 1):S1–S58.

    Article  Google Scholar 

  64. Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol. 1992;263:C1–16.

    Article  CAS  Google Scholar 

  65. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today. 2000;21:110–3.

    Article  CAS  Google Scholar 

  66. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Trans. 2007;35:1127e1132.

    Google Scholar 

  67. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38:1285e1291.

    Article  Google Scholar 

  68. Sofroniew MV. (2005). Reactive astrocytes in neural repair and protection. Neuroscientist 2005;11:400–407.

  69. Liu Y, Luo B, Han F, Li X, Xiong J, Jiang M, Yang X, Wu Y, Zhang Z. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One. 2014;9(3):e90942.

    Article  Google Scholar 

  70. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci. 2011;12:388–99.

    Article  CAS  Google Scholar 

  71. Zanier ER, Pischiutta F, Riganti L, Marchesi F, Turola E, Fumagalli S, Perego C, Parotto E, Vinci P, Veglianese P, D’Amico G, Verderio C, De Simoni MG. Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma. Neurotherapeutics. 2014;11(3):679–95.

    Article  CAS  Google Scholar 

  72. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6(6):484e494.

    Article  Google Scholar 

  73. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci. 2000;21:9733e9743.

    Google Scholar 

  74. Dhanushkodi A, Akano EO, Roguski EE, Xue Y, Rao SK, Matta SG, Rex TS, MP MD. A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism. Genes Brain Behav. 2013;12(2):224–33.

    Article  CAS  Google Scholar 

  75. Thomas Tayra J, Kameda M, Yasuhara T, Agari T, Kadota T, Wang F, Kikuchi Y, Liang H, Shinko A, Wakamori T, Vcelar B, Weik R, Date I. The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson’s disease. Brain Res. 2013;1502:55e70.

    Article  Google Scholar 

  76. Erbas O, Çınar BP, Solmaz V, Çavuşoğlu T, Ates U. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides. 2015;49:1e5.

    Article  Google Scholar 

Download references

Acknowledgements

The authors are deeply grateful to Professor Alfredo Gorio (University of Milan, Italy) for his scientific support and unswerving encouragement to the work. Dr. Zuzanna Gombalova participated in the research when she was visiting a student in the Laboratory of Pharmacology, Department of Health Sciences, University of Milan, supported by the Erasmus Program for PhD students. Dr. Federica Rey and Maria Carlotta F. Gorio are PhD student in the Nutritional Sciences, University of Milan. Federica Rey is supported by the Fondazione F.lli Confalonieri.

Funding

The authors acknowledge the economic support of the “Neurogel-en-Marche” Foundation (France) and AUS Niguarda Onlus (Italy) to AG and Fondazione “Romeo and Enrica Invernizzi” to AMDG.

Availability of data and materials

The data used in the current study are available if necessary.

Author information

Author notes

  1. Stephana Carelli and Toniella Giallongo contributed equally to this work.

Authors and Affiliations

  1. Laboratory of Pharmacology, Department of Health Sciences, University of Milan, Polo H. San Paolo, via A di Rudinì 8, 20142, Milan, Italy

    Stephana Carelli, Toniella Giallongo, Zuzana Gombalova, Federica Rey & Anna Maria Di Giulio

  2. Pediatric Clinical Research Center Fondazione Romeo e Enrica Invernizzi, University of Milan, Milan, Italy

    Stephana Carelli & Anna Maria Di Giulio

  3. Faculty of Science, Institute of Biology and Ecology, Pavol Jozef Safarik University in Kosice, Moyzesova 11, 04001, Kosice, Slovakia

    Zuzana Gombalova

  4. Department of Biomedical and Clinical Science L. Sacco, University of Milan, Milan, Italy

    Maria Carlotta F. Gorio

  5. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, FC, Italy

    Massimiliano Mazza

Authors
  1. Stephana Carelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toniella Giallongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zuzana Gombalova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federica Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Carlotta F. Gorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Massimiliano Mazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anna Maria Di Giulio
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SC contributed to the conception and design, data analysis and interpretation, and manuscript writing. TG performed the experiments, data analysis, and manuscript writing. ZG, FR, MCFG, and MM performed the experiments. AMDG contributed to the conception and design, data analysis and interpretation, financial support, and manuscript writing. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Stephana Carelli or Anna Maria Di Giulio.

Ethics declarations

Ethics approval

All animal experiments in this study have been approved by the Institutional Animal Care and Use Committee of Milan University, in accordance with the European Communities Directive of September 2010 (2010/63/UE) for the Care and Use of Laboratory Animals.

Consent for publication

Not applicable (no human data or tissues were used in this paper).

Competing interests

All the contributing authors have seen and approved the manuscript. All authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional files

Additional file 1:

Experimental plan. (PDF 214 kb)

Additional file 2:

Er-NPC-treated animals recover olfactory capabilities. Five groups of animals were analyzed with this test: 1) Control (CTRL, healthy animals, n = 24); 2) MPTP treated mice (MPTP, n = 24); 3) MPTP treated mice infused with PBS (SHAM, sham operated; n = 18); 4) MPTP treated mice transplanted with Er-NPCs (MPTP + Er-NPCs, n = 24) 5) MPTP treated mice transplanted with Er-NPCs and anti-erythropoietin antibody (MPTP + Er-NPCs + aEPO, n = 12). Data are expressed as mean ± SD. Statistical analysis was performed with two-way ANOVA test followed by Bonferroni post-test. °p < 0.05 vs CTRL; ***p < 0.001 vs MPTP. (PDF 197 kb)

Additional file 3:

Percentage of cells positive to CD11b, GFAP, and Iba1. Graphs report the stereologic counts of positive cells to investigated markers quantified in nine different fields for each condition (three mice for each group). The analysis was performed 2 weeks after Er-NPCs injection. Quantification was done by ImageJ picture analysis software. Data are expressed as mean ± SD. ***p < 0.001; **p < 0.01 vs CTRL; ###p < 0.001; ##p < 0.01 vs MPTP; °°°p < 0.001; °p < 0.05 vs MPTP + Er-NPCs ipsilateral; §§§p < 0.001 vs MPTP + Er-NPCs contralateral. (PDF 185 kb)

Additional file 4:

Percentage of cells positive to CD68, CD86, and CD206. Graphs report the stereological counts of positive cells to the investigated markers quantified in nine different fields for each condition (three mice for each group). The analyses were performed by evaluating nine different fields for each condition (three mice for each group). Quantification was done by ImageJ picture analysis software. Data are expressed as mean ± SD. ***p < 0.001; **p < 0.01; *p < 0.05 vs CTRL; ###p < 0.001; #p < 0.05 vs MPTP; °°°p < 0.001 vs MPTP + Er-NPCs ipsilateral; §§§p < 0.001; §p < 0.05 vs MPTP + Er-NPCs contralateral. (PDF 181 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carelli, S., Giallongo, T., Gombalova, Z. et al. Counteracting neuroinflammation in experimental Parkinson’s disease favors recovery of function: effects of Er-NPCs administration. J Neuroinflammation 15, 333 (2018). https://doi.org/10.1186/s12974-018-1375-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12974-018-1375-2

Keywords

Journal of Neuroinflammation

ISSN: 1742-2094